From: Prediction of health care expenditure increase: how does pharmacotherapy contribute?
All | Train | Validation | Test | |
---|---|---|---|---|
Patients, n (%) | 373′264 (100%) | 298′611 (80%) | 37′326 (10%) | 37′327 (10%) |
Demographics | ||||
Age, median [IQR] | 63.8 [49.2, 75.1] | 63.8 [49.3, 75.1] | 63.6 [49.0, 75.2] | 63.8 [49.1, 75.1] |
Gender [female], n (%) | 226′085 (60.6%) | 180′730 (60.5%) | 22′565 (60.5%) | 22′790 (61.1%) |
Language Area, n (%) | ||||
German | 275′025 (73.7%) | 219′998 (73.7%) | 27′469 (73.6%) | 27′558 (73.8%) |
French | 69′120 (18.5%) | 55′292 (18.5%) | 6′927 (18.6%) | 6′901 (18.5%) |
Italian | 29′119 (7.8%) | 23′321 (7.8%) | 2′930 (7.8%) | 2′868 (7.7%) |
Deductible, n (%) | ||||
CHF 300 | 250′287 (67.1%) | 200′211 (67.0%) | 25′026 (67.0%) | 25′050 (67.1%) |
CHF 500–1000 | 92′274 (24.7%) | 73′900 (24.7%) | 9′175 (24.6%) | 9′199 (24.6%) |
CHF > 1000 | 30′703 (8.2%) | 24′500 (8.2%) | 3′125 (8.4%) | 3′078 (8.2%) |
Cost | ||||
Total Costs (CHF), median [IQR] | 3′932 [1′944, 8′597] | 3′935 [1′946, 8′586] | 3′948 [1′958, 8′642] | 3′894 [1′915, 8′642] |
Cost Difference (CHF)*, median [IQR] | 93 [−1′746, 2365] | 93 [− 1′750, 2′365] | 62 [− 1′791, 2′305] | 122 [− 1′668, 2′441] |
Increase†, n (%) | 193′766 (51.9%) | 155′058 (51.9%) | 19′130 (51.3%) | 19′578 (52.4%) |
Drug Therapy | ||||
Number of drugs‡, median [IQR] | 9 [6, 15] | 9 [6, 15] | 9 [6, 15] | 9 [6, 15] |
Number of prescriptions§, median [IQR] | 19 [11, 34] | 19 [11, 34] | 19 [11, 34] | 19 [11, 34] |
Route of administration, n (%) | ||||
oral | 369'101 (98.9%) | 295′313 (98.9%) | 36′926 (98.9%) | 36′862 (98.8%) |
intravenous | 122′361 (32.8%) | 97′764 (32.7%) | 12′427 (33.3%) | 12′170 (32.6%) |
Health Care Utilisation | ||||
Number of visits||, median [IQR] | 8 [4, 13] | 8 [4, 13] | 8 [4, 13] | 8 [4, 13] |
Hospitalisation [yes], n (%) | 66′427 (17.8%) | 53′085 (17.8%) | 6′688 (17.9%) | 6′654 (17.8%) |